カナバン病:治療薬開発パイプライン動向(2016年下半期版)

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:DATA70209372)
◆英語タイトル:Canavan Disease - Pipeline Review, H2 2016
◆発行会社/調査会社:Global Markets Direct
◆商品コード:DATA70209372
◆発行日:2016年12月7日
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site LicenseUSD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[カナバン病:治療薬開発パイプライン動向(2016年下半期版)]についてメールでお問い合わせはこちら
当調査レポートでは、世界におけるカナバン病の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・カナバン病の概要
・カナバン病治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・カナバン病パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・カナバン病治療薬開発に取り組んでいる企業:企業別製品パイプライン
・カナバン病治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
*** レポート概要(サマリー)***

Canavan Disease – Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Canavan Disease – Pipeline Review, H2 2016, provides an overview of the Canavan Disease (Central Nervous System) pipeline landscape.

Canavan disease is a gene-linked neurological disorder in which the brain degenerates into spongy tissue riddled with microscopic fluid-filled spaces. Cause includes a mutation in the gene which directs the production of the enzyme aspartoacylase (ASPA) allows the buildup of N-acetylaspartic acid (NAA) in the brain. The buildup of NAA causes damage to myelin. Symptoms include lack of motor development, feeding difficulties, abnormal muscle tone, and an abnormally large, poorly controlled head, paralysis, blindness, or hearing loss.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Canavan Disease – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Canavan Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Canavan Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Canavan Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.Canavan Disease.

Canavan Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Canavan Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Canavan Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Canavan Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Canavan Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Canavan Disease (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Canavan Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Canavan Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Canavan Disease Overview 5
Therapeutics Development 6
Pipeline Products for Canavan Disease – Overview 6
Pipeline Products for Canavan Disease – Comparative Analysis 7
Canavan Disease – Therapeutics under Development by Companies 8
Canavan Disease – Therapeutics under Investigation by Universities/Institutes 9
Canavan Disease – Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Canavan Disease – Products under Development by Companies 12
Canavan Disease – Products under Investigation by Universities/Institutes 13
Canavan Disease – Companies Involved in Therapeutics Development 14
Turing Pharmaceuticals AG 14
Canavan Disease – Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Target 16
Assessment by Mechanism of Action 17
Assessment by Molecule Type 19
Drug Profiles 21
Gene Therapy 2 to Activate Aspartoacylase for Canavan Disease – Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
Gene therapy to Activate Aspartoacylase for Canavan Disease – Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
Recombinant Enzyme to Replace Aspartoacylase for Canavan Disease – Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
Stem Cell Therapy to Activate Aspartoacylase for Canavan Disease – Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
TUR-007 – Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Canavan Disease – Dormant Projects 26
Canavan Disease – Discontinued Products 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 28
Disclaimer 29

List of Tables
Number of Products under Development for Canavan Disease, H2 2016 6
Number of Products under Development for Canavan Disease - Comparative Analysis, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Number of Products under Investigation by Universities/Institutes, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Products under Investigation by Universities/Institutes, H2 2016 13
Canavan Disease - Pipeline by Turing Pharmaceuticals AG, H2 2016 14
Assessment by Monotherapy Products, H2 2016 15
Number of Products by Stage and Target, H2 2016 16
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 20
Canavan Disease - Dormant Projects, H2 2016 26
Canavan Disease - Discontinued Products, H2 2016 27

List of Figures
Number of Products under Development for Canavan Disease, H2 2016 6
Number of Products under Development for Canavan Disease - Comparative Analysis, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy Products, H2 2016 15
Number of Products by Stage and Targets, H2 2016 16
Number of Products by Mechanism of Actions, H2 2016 17
Number of Products by Stage and Mechanism of Actions, H2 2016 17
Number of Products by Molecule Types, H2 2016 19
Number of Products by Stage and Molecule Types, H2 2016 19

*** レポートのキーワード ***

カナバン病

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
  • 世界及び中国のパーフルオロエチレンプロピレン(FEP)市場2009-2019
    Market Research Report on Global and Chinese Perfluoroethylene-propylene(FEP) Industry, 2009-2019 is a professional and in-depth market survey on Global and Chinese Perfluoroethylene-propylene(FEP) industry. The report firstly reviews the basic information of Perfluoroethylene-propylene(FEP) includi …
  • 食品コーティングの世界市場予測(~2023年):バッター、小麦粉
    The Food Coating Market is projected to reach 5,936.3 USD Million by 2023 at a CAGR of 4.98% from 2018-2023. The food coating ingredients and equipment markets are estimated to be valued at USD 2.73 billion and USD 1.93 billion, respectively, in 2018 and are projected to reach a value of USD 3.62 bi …
  • オランダの旅行保険及びアシスタンス市場
    Finaccord’s report titled Travel Insurance and Assistance in the Netherlands is about the current status and likely future development of the market for stand-alone travel insurance policies in the Netherlands. It includes the following unique features: - data spanning 2010 to 2014 for the underlyin …
  • 世界及び中国のハフニウム粉市場
    Global and Chinese Hafnium Powder Industry, 2009-2019 Market Research Report is a professional and in-depth market survey on Global and Chinese Hafnium Powder industry. The report firstly reviews the basic information of Hafnium Powder including its classification, application and manufacturing tech …
  • コスタリカのスマートフォン市場(~2015):ベンダー別販売量
    Summary "Costa Rica Smartphone Market to 2015: Mobile Handset Sales by Vendor" report provides a top-level overview and detailed insights into the operating environment for mobile operators. It is an essential tool for companies active across the telecom value chain in Costa Rica and for new compani …
  • 世界及び中国のテトラシラン市場2009-2019
    Market Research Report on Global and Chinese Tetrasilane Industry, 2009-2019 is a professional and in-depth market survey on Global and Chinese Tetrasilane industry. The report firstly reviews the basic information of Tetrasilane including its classification, application and manufacturing technology …
  • The Emirates Group : 企業概要及びSWOT分析
    This SWOT analysis and company profile is a crucial resource for industry executives and anyone looking to gain a better understanding of the company's business. WMI's 'The Emirates Group : Company Profile and SWOT Analysis' report utilizes a wide range of primary and secondary sources, which are an …
  • 世界のカーボンファイバーラップ市場2017
    Carbon Fiber Wrap Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germ …
  • フランスの発電市場2016:市場動向、制度、競争状況
    France Power Market Outlook to 2030, Update 2016 - Market Trends, Regulations, and Competitive Landscape Summary This report elaborates France's power market structure and provides historical and forecast numbers for generation, capacity and consumption up to 2030. Detailed analysis of the France po …
  • 世界及び中国のレパグリニド市場2017
    The 'Global and Chinese Repaglinide Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Repaglinide industry with a focus on the Chinese market. The report provides key statistics on the market status of the Repaglinide manufacturers an …
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DATA70209372 )"カナバン病:治療薬開発パイプライン動向(2016年下半期版)" (英文:Canavan Disease - Pipeline Review, H2 2016)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。